Expansion of NK cells and therapeutic uses thereof
AssigneeSt. Jude Children's Research Hospital
InventorsDario Campana, Chihaya Imai
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.
Claims3
A modified cell line comprising cells that lack major histocompatibility complex I molecules wherein said cells are genetically modified to express membrane bound interleukin-15 and a co-stimulatory factor ligand CD137L, where said modified cell line activates natural killer (NK) cells and fails to activate T lymphocytes.
A method of preferentially expanding natural killer (NK) cells in a mixed cell culture comprising NK cells and T lymphocytes which comprises culturing said mixed cell culture with a modified cell line comprising cells that lack major histocompatibility complex I molecules wherein said cells are genetically modified to express membrane bound interleukin-15 and a co-stimulatory factor ligand CD137L, where said modified cell line activates natural killer (NK) cells and fails to activate T lymphocytes.
Dependencies are inferred from the claim text.